274 related articles for article (PubMed ID: 19430285)
21. Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to central retinal vein occlusion: results of the pan American collaborative retina study group at 24 months.
Wu L; Arevalo JF; Berrocal MH; Maia M; Roca JA; Morales-Cantón V; Alezzandrini AA; Díaz-Llopis MJ
Retina; 2010; 30(7):1002-11. PubMed ID: 20616679
[TBL] [Abstract][Full Text] [Related]
22. Intravitreal bevacizumab and/or macular photocoagulation as a primary treatment for diffuse diabetic macular edema.
Solaiman KA; Diab MM; Abo-Elenin M
Retina; 2010; 30(10):1638-45. PubMed ID: 20838357
[TBL] [Abstract][Full Text] [Related]
23. Bevacizumab (Avastin) for diabetic macular edema in previously vitrectomized eyes.
Yanyali A; Aytug B; Horozoglu F; Nohutcu AF
Am J Ophthalmol; 2007 Jul; 144(1):124-6. PubMed ID: 17601433
[TBL] [Abstract][Full Text] [Related]
24. Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema.
Kumar V; Ghosh B; Raina UK; Goel N
Am J Ophthalmol; 2008 Dec; 146(6):974; author reply 974-5. PubMed ID: 19027427
[No Abstract] [Full Text] [Related]
25. The effect of unilateral intravitreal bevacizumab (avastin), in the treatment of diffuse bilateral diabetic macular edema: a pilot study.
Velez-Montoya R; Fromow-Guerra J; Burgos O; Landers MB; Morales-Catón V; Quiroz-Mercado H
Retina; 2009 Jan; 29(1):20-6. PubMed ID: 18784623
[TBL] [Abstract][Full Text] [Related]
26. Intravitreal bevacizumab (avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema.
Soheilian M; Ramezani A; Bijanzadeh B; Yaseri M; Ahmadieh H; Dehghan MH; Azarmina M; Moradian S; Tabatabaei H; Peyman GA
Retina; 2007; 27(9):1187-95. PubMed ID: 18046223
[TBL] [Abstract][Full Text] [Related]
27. Intravitreal bevacizumab (Avastin) for primary treatment of diabetic macular oedema.
Ozkiriş A
Eye (Lond); 2009 Mar; 23(3):616-20. PubMed ID: 18437176
[TBL] [Abstract][Full Text] [Related]
28. Comparison of intravitreal bevacizumab alone or combined with triamcinolone versus triamcinolone in diabetic macular edema: a randomized clinical trial.
Lim JW; Lee HK; Shin MC
Ophthalmologica; 2012; 227(2):100-6. PubMed ID: 21997197
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of 1.25 MG versus 2.5 MG intravitreal bevacizumab for diabetic macular edema: six-month results of a randomized controlled trial.
Lam DS; Lai TY; Lee VY; Chan CK; Liu DT; Mohamed S; Li CL
Retina; 2009 Mar; 29(3):292-9. PubMed ID: 19287286
[TBL] [Abstract][Full Text] [Related]
30. Phacoemulsification with intravitreal bevacizumab injection in diabetic patients with macular edema and cataract.
Akinci A; Batman C; Ozkilic E; Altinsoy A
Retina; 2009; 29(10):1432-5. PubMed ID: 19898181
[TBL] [Abstract][Full Text] [Related]
31. Improvement of diabetic retinopathy with intravitreal Ranibizumab.
Kernt M; Cserhati S; Seidensticker F; Liegl R; Kampik A; Neubauer A; Ulbig MW; Reznicek L
Diabetes Res Clin Pract; 2013 Apr; 100(1):e11-3. PubMed ID: 23391744
[TBL] [Abstract][Full Text] [Related]
32. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2.
Michaelides M; Kaines A; Hamilton RD; Fraser-Bell S; Rajendram R; Quhill F; Boos CJ; Xing W; Egan C; Peto T; Bunce C; Leslie RD; Hykin PG
Ophthalmology; 2010 Jun; 117(6):1078-1086.e2. PubMed ID: 20416952
[TBL] [Abstract][Full Text] [Related]
33. Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema.
Shimura M; Nakazawa T; Yasuda K; Shiono T; Iida T; Sakamoto T; Nishida K
Am J Ophthalmol; 2008 May; 145(5):854-61. PubMed ID: 18328456
[TBL] [Abstract][Full Text] [Related]
34. Effect of diabetic macular edema on peripapillary retinal nerve fiber layer thickness profiles.
Hwang DJ; Lee EJ; Lee SY; Park KH; Woo SJ
Invest Ophthalmol Vis Sci; 2014 May; 55(7):4213-9. PubMed ID: 24833740
[TBL] [Abstract][Full Text] [Related]
35. Correspondence.
Rajpal S; Narula R; Agarwal M; Chaudhary SP
Retina; 2010; 30(7):1160; author reply 1160. PubMed ID: 20616693
[No Abstract] [Full Text] [Related]
36. Intravitreal fasudil combined with bevacizumab for persistent diabetic macular edema: a novel treatment.
Ahmadieh H; Nourinia R; Hafezi-Moghadam A
JAMA Ophthalmol; 2013 Jul; 131(7):923-4. PubMed ID: 23640178
[No Abstract] [Full Text] [Related]
37. Intravitreal bevacizumab (Avastin) injection in retinitis pigmentosa.
Yuzbasioglu E; Artunay O; Rasier R; Sengul A; Bahcecioglu H
Curr Eye Res; 2009 Mar; 34(3):231-7. PubMed ID: 19274531
[TBL] [Abstract][Full Text] [Related]
38. Intravitreal bevacizumab for persistent macular edema with proliferative diabetic retinopathy.
Gulkilik G; Taskapili M; Kocabora S; Muftuoglu G; Demirci G
Int Ophthalmol; 2010 Dec; 30(6):697-702. PubMed ID: 20936526
[TBL] [Abstract][Full Text] [Related]
39. Ischemic maculopathy following intravitreal bevacizumab for refractory diabetic macular edema.
Goel N; Kumar V; Ghosh B
Int Ophthalmol; 2011 Feb; 31(1):39-42. PubMed ID: 20852916
[TBL] [Abstract][Full Text] [Related]
40. Intravitreal injection of ranibizumab during cataract surgery in patients with diabetic macular edema.
Rauen PI; Ribeiro JA; Almeida FP; Scott IU; Messias A; Jorge R
Retina; 2012 Oct; 32(9):1799-803. PubMed ID: 22495327
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
